Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Feb 21;16(8):1335–1348. doi: 10.7150/ijbs.41130

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Activated TAK1 reverses the protective effects of TBC1D25 on cardiomyocytes hypertrophy induced by Ang II. (A) Representative western blots of TBC1D25 and in AdGFP, AdTBC1D25, AdGFP+AdcaTAK1 or AdTBC1D25+AdcaTAK1 infected NRCMs. (B) Representative images of cardiomyocytes (immunostained with the α-actinin antibody) infected with AdGFP, AdTBC1D25, AdGFP+AdcaTAK1 or AdTBC1D25+AdcaTAK1 after treatment with Ang II (left). Quantification of cell surface area (right). Left, n=3 independent experiments. Right, n=50 cells per group. Scale bar, 20 μm. (C) ANP and BNP mRNA levels in NRCMs treated Ang II in each group. *P<0.05 vs AdGFP group, **P<0.01 vs AdGFP group, ^##P<0.01 vs AdTBC1D25 group. n.s. indicates no significance.